The Critical Investor Shares His Top 7 Picks for 2022
Source: The Critical Investor  (1/9/22)
The Critical Investor was asked again by Streetwise Reports to provide his top 7 picks for the new year — at a point where the COVID-19 pandemic is playing out the Omicron variant, inflation is reaching levels not seen in decades, the Fed surprising the markets with a more hawkish stance than anticipated, with metal prices at very high levels although gold and silver seem to be consolidating and setting up for a breakout. More >

Co.'s samRNA Vaccines Protect Better Against COVID Variants
  (1/7/22)
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio. More >

AI Driven Drug Firm Partners With Merck
Source: Streetwise Reports  (1/7/22)
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creationâ„¢ platform and Bionic Proteinâ„¢ technologies. More >

Logiq Board OKs Splitting Into 2 Companies
Source: Streetwise Reports  (1/6/22)
E-commerce customer acquisition solutions company Logiq Inc. plans to separate into two publicly traded companies this month, President and Executive Chairman Brent Suen says. More >

2022 Could See Shipping Co. Dividends, Buybacks
  (1/6/22)
Noble Capital Markets has an Outperform rating and a $45 per share price target on Euroseas Ltd. given the company's favorable outlook for 2022. More >

Silver, Gold Could Outperform Industrial Metals in 2022
  (1/6/22)
Mining companies finished 2021 strongly with a 7.3% gain in Q4/21, reported Noble Capital Markets in a research note. More >

Co. Partners to Test New Cancer Vaccines
  (1/6/22)
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigensâ„¢ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea. More >

Medical Co. Strikes $3B Deal to Buy Digital Care Firm
Source: Streetwise Reports  (1/6/22)
Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash. More >

Analyst Says Co.'s Stock Could Skyrocket
Source: Clive Maund  (1/6/22)
Analyst Clive Maund says Kainantu Resources Ltd.'s stock could take off if it makes a discovery at its properties in Papua New Guinea. More >

Chen Lin's Top 6 Investment Ideas
Source: Streetwise Reports  (1/5/22)
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022. More >

New Muscular Dystrophy Drug Shows Promise
Source: Streetwise Reports  (1/5/22)
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial. More >

Firm to Start Exploration After Survey Results
  (1/5/22)
Results of a three-dimensional interpretation of a survey at its Eskay claims could be a major catalyst for Garibaldi Resources, Noble Capital Markets said in a research note. More >

Co. Plans to Make 100M Rapid COVID Tests Monthly
  (1/5/22)
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22. More >

Tech Growth Pushes Co.'s Rating Higher
  (1/4/22)
"We expect strong datacom sales will enable II-VI to exceed Street expectations [in 2022]," noted a Raymond James report. More >

Oilfield Services Co. Projects 25% Revenue Growth for Q4
Source: Streetwise Reports  (1/4/22)
Shares of land-focused oil services firm NexTier Oilfield Solutions Inc. traded 27% higher after the company reported it expects Q4/21 revenues will be in the range of $500-510 million and advised that its 32-unit fracking rig fleet will be fully deployed in Q1/22. More >

Skyharbour Looks to New Uranium Claims
Source: Streetwise Reports  (1/3/22)
Skyharbour Resources Ltd. has staked six new prospective uranium exploration properties within and near the Athabasca Basin of northern Saskatchewan, which contains the world’s highest-grade uranium deposits. More >

Imperial Helium Expects Its First Sales in 2022
Source: Streetwise Reports  (1/3/22)
Imperial Helium’s second, future-producing helium well was spud on Dec. 6, 2021, amidst constrained global helium supply. The outlook is good for 2022. More >

Lead Cancer Drug Gets Fast Tracked
Source: Streetwise Reports  (1/3/22)
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSAâ„¢ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment. More >

Analyst: Drug a 'Hidden Gem for 2022'
  (12/31/21)
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish." More >

Why This Gold Newcomer Is a 'Strong Buy'
Source: Streetwise Reports  (12/30/21)
Sitka Gold Corp's recently released new drill results at its RC Gold Project in the Yukon have grabbed investors' attention. More >

Co.'s COVID-19 Test Detects Omicron Variant
  (12/30/21)
H.C. Wainwright & Co. gives Sorrento Therapeutics a Buy rating after initial testing shows its COVISTIX detects COVID-19's Omicron variant. More >

Tech Firm Surging In Mobile Gaming Market
  (12/30/21)
"Pixelworks represents a differentiated investment opportunity in video display processing capabilities," noted a ROTH Capital Partners report. More >

Why Red Metal Resources Is a Standout
Source: BioResearchAlert  (12/30/21)
With copper continuing to soar and Chile electing a new president opposed to open pit mines, Red Metal Resources is a compelling standout. More >

Co. Looks To US For Help Fighting Strokes
Source: Streetwise Reports  (12/29/21)
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs. More >

Co. Still Compelling After Drug Trial Failure
  (12/29/21)
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report. More >